Learn About Ongoing Research Studies

Dravet Syndrome Research Study

This study is looking at treating patients diagnosed with Dravet's Syndrome at least 2 years of age and up with lorcaserin. Study participation will last approximately 34 weeks. The first 18 weeks is a double-bind, meaning there is a chance of receiving placebo. The last 16 weeks will be open label meaning the patient will receive study drug. Any interested candidates should reach out to Brittany Hirth at Brittany.Hirth@UHhospitals.org or by phone at 216-844-8270.

STUDY OPPORTUNITY
SMART 2.0

If you are a person living with epilepsy in Ohio or Iowa, you might quality for the SMART 2.0 research study. 

>>Click here for the flyer that contains the program details

Contact persons:
Iowa - Maegan Tyrrell at (319) 353-6550 maegantyrrell@uiowa.edu
Ohio - Kari Colón- Zimmermann at (216) 844- 2102 or kmz24@case.edu